176 related articles for article (PubMed ID: 37792394)
1. Effects of the Acute and Chronic Administration of Cannabidiol on Cognition in Humans and Animals: A Systematic Review.
Bomfim AJL; Zuze SMF; Fabrício DM; Pessoa RMP; Crippa JAS; Chagas MHN
Cannabis Cannabinoid Res; 2023 Dec; 8(6):955-973. PubMed ID: 37792394
[No Abstract] [Full Text] [Related]
2. The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
Cannabis Cannabinoid Res; 2024 Feb; 9(1):230-240. PubMed ID: 35881851
[No Abstract] [Full Text] [Related]
3. Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder.
Lees R; Hines LA; Hindocha C; Baio G; Shaban NDC; Stothart G; Mofeez A; Morgan CJA; Curran HV; Freeman TP
Psychopharmacology (Berl); 2023 Feb; 240(2):337-346. PubMed ID: 36598543
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.
Osborne AL; Solowij N; Weston-Green K
Neurosci Biobehav Rev; 2017 Jan; 72():310-324. PubMed ID: 27884751
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of cannabidiol trials in neurodevelopmental disorders.
Parrella NF; Hill AT; Enticott PG; Barhoun P; Bower IS; Ford TC
Pharmacol Biochem Behav; 2023 Sep; 230():173607. PubMed ID: 37543051
[TBL] [Abstract][Full Text] [Related]
6. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
[TBL] [Abstract][Full Text] [Related]
7. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
[TBL] [Abstract][Full Text] [Related]
8. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy.
Martin RC; Gaston TE; Thompson M; Ampah SB; Cutter G; Bebin EM; Szaflarski JP
Epilepsy Behav; 2019 Aug; 97():105-110. PubMed ID: 31220785
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations.
Aziz AI; Nguyen LC; Oumeslakht L; Bensussan A; Ben Mkaddem S
Cannabis Cannabinoid Res; 2023 Apr; 8(2):254-269. PubMed ID: 36413346
[No Abstract] [Full Text] [Related]
10. Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders.
Osborne AL; Solowij N; Babic I; Lum JS; Huang XF; Newell KA; Weston-Green K
Brain Behav Immun; 2019 Oct; 81():574-587. PubMed ID: 31326506
[TBL] [Abstract][Full Text] [Related]
11. Effects of daily Δ
Withey SL; Kangas BD; Charles S; Gumbert AB; Eisold JE; George SR; Bergman J; Madras BK
Drug Alcohol Depend; 2021 Apr; 221():108629. PubMed ID: 33640678
[TBL] [Abstract][Full Text] [Related]
12. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
13. Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy.
Metternich B; Wagner K; Geiger MJ; Hirsch M; Schulze-Bonhage A; Klotz KA
Epilepsy Behav; 2021 Jan; 114(Pt A):107558. PubMed ID: 33246899
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
[TBL] [Abstract][Full Text] [Related]
15. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
[TBL] [Abstract][Full Text] [Related]
16. Subjective, behavioral and neurobiological effects of cannabis and cannabinoids in social anxiety.
Rosário BDA; Lemes JA; de Lima MP; Ribeiro DA; Viana MB
Rev Neurosci; 2024 Feb; 35(2):197-211. PubMed ID: 37812748
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: A systematic review.
Rodrigues LA; Caroba MES; Taba FK; Filev R; Gallassi AD
Pharmacol Biochem Behav; 2020 Sep; 196():172982. PubMed ID: 32645315
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral Δ9-tetrahydrocannabinol and cannabidiol combinations on a sustained attention task in rats.
Moore CF; Davis CM; Sempio C; Klawitter J; Christians U; Weerts EM
Exp Clin Psychopharmacol; 2023 Oct; 31(5):881-887. PubMed ID: 36634015
[TBL] [Abstract][Full Text] [Related]
19. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid treatments in epilepsy and seizure disorders.
Devinsky O; Jones NA; Cunningham MO; Jayasekera BAP; Devore S; Whalley BJ
Physiol Rev; 2024 Apr; 104(2):591-649. PubMed ID: 37882730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
